BAFF, produced by monocytic and dendritic cells, is targeted by Belimumab, a monoclonal antibody that can bind receptors on different mature B cells: it was evaluated in a phase II trial in AChR-positive MG (ClinicalTrials.gov, NCT01480596) [140] but did not show any significant difference in clinical scores [141]. This evidence concerns the gene TNFSF13B and myasthenia gravis.